Wooters, T. ., Smith, A. ., Pivavarchyk, M. ., Siripurapu, K. ., McIntosh, J. ., Zhang, Z. ., … Dwoskin, L. . (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Smith, A. ., Pivavarchyk, M. ., Wooters, T. ., Zhang, Z. ., Zheng, G. ., McIntosh, J. ., … Dwoskin, L. . (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)

Dwoskin, L. ., Wooters, T. ., Sumithran, S. ., Siripurapu, K. ., Joyce, B. ., Lockman, P. ., … Bardo, M. . (2008). N,N’-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal of Pharmacology and Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630

Beckmann, J. ., Meyer, A. ., Pivavarchyk, M. ., Horton, D. ., Zheng, G. ., Smith, A. ., … Dwoskin, L. . (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4